GPC3 and neoplasm: To control the expression of IL12, we then engineered NK92 cells with anti-GPC3 synNotch receptors to produce IL12 (“GPC3-Syn-IL12-NK92”) in the presence of GPC3-positive tumor cells (Figure 2A).